ALVO OAKTREE ACQUISITION CORP II

Viðskipti stjórnenda og tengdra aðila

Viðskipti stjórnenda og tengdra aðila

Í viðhengi er tilkynning um viðskipti stjórnenda og tengdra aðila sem send var inn til fjármálaeftirlits Lúxemborgar, Luxembourg Commission de Surveillance du Secteur Financier (CSSF), varðandi kaup Richards Davies, varaformanns stjórnar Alvotech á 19.988 hlutum í Alvotech á genginu 10,18 Bandaríkjadalir á hlut. Viðskiptin eru dagsett miðvikudaginn 14. maí sl. 

Viðhengi



EN
16/05/2025

Underlying

ALVOOAKTREE ACQUISITION CORP II

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on OAKTREE ACQUISITION CORP II

 PRESS RELEASE
Free
ALVO OAKTREE ACQUISI...

Transactions of Managers and Closely Associated Persons

Transactions of Managers and Closely Associated Persons Attached are copies of two filings with the Luxembourg Commission de Surveillance du Secteur Financier (CSSF) regarding transactions of managers and closely associated persons. ATP Holdings ehf. announced a sale of 2,701,617 shares in Alvotech on January 30, 2026, and Aztiq Pharma Partners S.à r.l. ("Aztiq") announced the acquisition of 2,701,617 shares in Alvotech on January 30, 2026. ATP Holdings ehf. belongs to the Aztiq group and the transaction was thus a transfer of shares within the group. The announcements related to the same t...

2m 1 EN
 PRESS RELEASE
Free
ALVO OAKTREE ACQUISI...

Viðskipti stjórnenda og tengdra aðila

Viðskipti stjórnenda og tengdra aðila Í viðhengi eru tvær tilkynningar um viðskipti stjórnenda og tengdra aðila sem lagðar voru inn til birtingar hjá fjármálaeftirliti Lúxemborgar, Luxembourg Commission de Surveillance du Secteur Financier (CSSF). ATP Holdings ehf. tilkynnti um sölu á 2.701.617 bréfum þann 30. janúar sl. og Aztiq Pharma Partners S.à r.l. ("Aztiq") um kaup á 2.701.617 bréfum þann 30. janúar sl. ATP Holdings ehf. er í sömu samstæðu og Aztiq og var því um að ræða flutning bréfanna innan samstæðunnar. Tilkynningarnar vörðuðu sömu viðskipti og verð bréfanna í viðskiptunum var 4,...

2m 1 EN
 PRESS RELEASE
Free
ALVO OAKTREE ACQUISI...

Alvotech Announces Increase in Number of Own Shares

Alvotech Announces Increase in Number of Own Shares REYKJAVIK, ICELAND (February 11, 2026) — Alvotech (NASDAQ: ALVO) (the “Company”), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, has increased the Company´s share capital by an amount of one hundred and twenty-five thousand (USD 125,000) by issuing twelve million and five-hundred thousand (12,500,000) ordinary shares. The Company’s subsidiary, Alvotech Manco ehf. (the “subsidiary”), has subscribed to all of the newly issued shares for a price of USD 5.2 per share. Th...

February 11, 2026 1 EN
 PRESS RELEASE
Free
ALVO OAKTREE ACQUISI...

Alvotech tilkynnir um aukningu í fjölda eigin bréfa

Alvotech tilkynnir um aukningu í fjölda eigin bréfa REYKJAVIK (11. febrúar 2026) - Alvotech (NASDAQ: ALVO) tilkynnti í dag að stjórn fyrirtækisins hefði ákveðið að gefa út tólf og hálfa milljón (12.500.000) nýrra almennra hluta í félaginu. Dótturfélag Alvotech, Alvotech Manco ehf. („dótturfélagið“) kaupir öll bréfin af móðurfélaginu á genginu 5,2 bandaríkjadalir á hlut. Hlutir dótturfélagsins eru taldir til eigin hlutabréfa Alvotech og fylgir þeim því hvorki atkvæðisréttur né réttur til arðgreiðslu. Að loknum þessum viðskiptum á dótturfélagið alls 16.254.005 hluti, eða um 4,7% útgefinna hl...

February 11, 2026 1 EN
 PRESS RELEASE
Free
ALVO OAKTREE ACQUISI...

Alvotech Announces Positive Top-Line Results from Pivotal Pharmacokine...

Alvotech Announces Positive Top-Line Results from Pivotal Pharmacokinetic Study for Proposed Biosimilar to Entyvio® The study, which assessed the pharmacokinetics, safety, tolerability and immunogenicity of AVT80 compared to Entyvio® in healthy adult participants, met all its primary endpoints REYKJAVIK, ICELAND (February 5, 2026) – Alvotech (NASDAQ: ALVO), a global biotechnology company specializing in the development and manufacture of biosimilar medicines for patients worldwide, announced today positive top-line results from a pharmacokinetic (PK) study for AVT80, a biosimilar candidat...

February 5, 2026 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch